During the forecast period 2023 to 2033, the Gastroesophageal Junction Adenocarcinoma Therapeutics market is expected to grow at a value of 18% CAGR, according to Future Market Insights. By the year 2033, the global market for Gastroesophageal Junction Adenocarcinoma Therapeutics is expected to rise up to a market valuation of US$ 34.3 Billion. Growth of the market can be attributed to increasing prevalence of the disease. According to a recent report by the American Cancer Society, the incidence of GEJAC has been steadily increasing over the past several years, particularly among older adults. As a result, there is a growing need for effective treatments to combat this disease.
For Details on Vendors and Their Offerings – Request A Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16787
Another important factor driving the growth of the GEJAC therapeutics market is the increasing availability of targeted therapies. Targeted therapies are drugs that specifically target cancer cells while sparing healthy cells, which can result in fewer side effects and better outcomes for patients. There are now several targeted therapies approved for the treatment of GEJAC, including trastuzumab and ramucirumab, and more are expected to become available in the coming years.
One promising area of research in the GEJAC therapeutics market is the development of immunotherapies. Immunotherapies are drugs that harness the power of the immune system to fight cancer cells. There are now several immunotherapies approved for the treatment of other types of cancer, and researchers are actively exploring their potential for treating GEJAC as well.
Key Takeaways from the Market Study
- The Gastroesophageal Junction Adenocarcinoma Therapeutics market is expected to grow at a value of 18% in the forecast period 2023 to 2033.
- By treatment, Esophagectomy surgery is expected to possess 40% market share for GEJAC market in 2023.
- Europe is expected to possess 37% market share for GEJAC market in 2023.
- North America is expected to possess 44% market share for GEJAC market in 2023.
“The increasing adoption of targeted therapies and personalized medicine is expected to drive market growth.” states an FMI analyst
Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-16787
Competitive Landscape
Key players in the Gastroesophageal Junction Adenocarcinoma Therapeutics market are Astellas Pharmaceuticals, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Daichii Sankyo, Elevar Therapeutics, Eli Lilly, FivePrime Therapeutics, Incyte, Macrogenics, Merck Co, Ono Pharmaceuticals, Roche, Taiho Pharmaceuticals, Zai Labs, ZymeWorks
- Bayer has been involved in the development of several drugs that may have potential in the treatment of GEJAC. One such drug is Stivarga (regorafenib), a multi-kinase inhibitor that is approved for the treatment of several types of cancer, including colorectal cancer and gastrointestinal stromal tumors (GIST)
- BeiGene has been involved in the development of several drugs that may have potential in the treatment of gastroesophageal junction adenocarcinoma (GEJAC). One such drug is Pamiparib (BGB-290), a PARP inhibitor that is being evaluated in several clinical trials for the treatment of various types of cancer, including GEJAC.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Gastroesophageal Junction Adenocarcinoma Therapeutics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Buy Now to Gain Access to Detailed Information About Each Segment and Identify Key Trends, Drivers, and Challenges in the Market@ https://www.futuremarketinsights.com/checkout/16787
Key Segments Profiled in the Gastroesophageal Junction Adenocarcinoma Therapeutics Market Survey
Drug:
- Trastuzumab
- Ramucirumab
Diagnosis:
- Endoscopy
- X-ray
- CT Scan
- PET Scan
Treatment:
- Esophagectomy surgery
- Esophageal dilation
- Chemotherapy
- Targeted therapy
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
About the Healthcare at Future Market Insights
The healthcare domain team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 Billion+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
